Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China · Delayed Price · Currency is CNY 6.40
+0.43 (7.20%)
Apr 15, 2026, 3:00 PM CST
SHA:600713 Revenue
In the year 2025, Nanjing Pharmaceutical Group Company had annual revenue of 54.96B CNY with 2.36% growth. Nanjing Pharmaceutical Group Company had revenue of 13.83B in the quarter ending December 31, 2025, with 8.39% growth.
Revenue
54.96B
Revenue Growth
+2.36%
P/S Ratio
0.15
Revenue / Employee
11.38M
Employees
4,830
Market Cap
8.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.96B | 1.27B | 2.36% |
| Dec 31, 2024 | 53.70B | 106.51M | 0.20% |
| Dec 31, 2023 | 53.59B | 3.37B | 6.71% |
| Dec 31, 2022 | 50.22B | 5.10B | 11.30% |
| Dec 31, 2021 | 45.12B | 5.31B | 13.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Int'l Group | 33.54B |
| Yifan Pharmaceutical | 5.22B |
| Zhejiang Jolly Pharmaceutical Co.,LTD | 2.81B |
| GuangYuYuan Chinese Herbal Medicine | 1.39B |
| Zhejiang Wolwo Bio-Pharmaceutical | 1.05B |
| Shanghai InnoStar Bio-tech | 811.33M |
| Chongqing Lummy Pharmaceutical | 775.69M |
| Hangzhou Minsheng Healthcare | 744.06M |